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Cough swabs less useful but induced sputum very useful in 
symptomatic older children with cystic fibrosis
Microbiological surveillance continues to be an 
important aspect of cystic fibrosis care.1,2 In young 
children, such surveillance is complicated by the inability 
to expectorate sputum. Thus, cough swabs are routinely 
used to obtain samples, and some cystic fibrosis centres 
use regular bronchoalveolar lavage or induced sputum 
sampling.
In The Lancet Respiratory Medicine, Katherine Ronchetti 
and colleagues3 compared the diagnostic yield of 
bacterial culture results from 167 paired induced 
sputum and cough swab samples in patients aged 
6 months to 18 years.3 In a subset of their study they 
compared bacterial yield from induced sputum to 
bronchoalveolar lavage.  Induced sputum samples had 
a significantly higher bacterial yield than cough swab 
samples: 86 different pathogens were isolated in total 
from the samples, and 79 [92%] of these were identified 
by sputum induction whereas 27 [31%] were on cough 
swab samples (p<0·0001). This difference suggests that 
induced sputum can detect pathogens from the lower 
airways that cough swabs cannot. A strength of this 
first stage of the study was high participant numbers: 
124 patients were recruited from whom 167 paired 
samples were successfully taken. Children younger 
than 6 years were also well represented in this part 
of the study (n=72). In view of these results, induced 
sputum appears to be far superior to cough swab for 
detection of lower airway pathogens in patients with 
cystic fibrosis. These findings are useful and consistent 
with other studies that showed improved microbial 
yield of induced sputum over upper-airway sampling in 
children.4,5 The poor diagnostic value of cough swabs is 
also consistent with other findings that oropharyngeal 
swabs bear little-to-no relation to lower-airway 
pathology in young children with cystic fibrosis.6
In a subset of largely symptomatic patients, 
Ronchetti and colleagues compared bacterial culture 
yield from 41 paired induced sputum samples and 
single-lobe, two-lobe, and six-lobe bronchoalveolar 
lavages. Sequentially more pathogens were isolated 
with bronchoalveolar lavage as more lobes were 
lavaged. Sputum induction isolated 27 (69%) of the 
39 total pathogens detected by both techniques versus 
22 (56%) on single-lobe bronchoalveolar lavage, 
28 (72%) on two-lobe bronchoalveolar lavage, and 
33 (85%) on six-lobe bronchoalveolar lavage. Because 
different pathogens were detected between induced 
sputum and bronchoalveolar lavage, Ronchetti and 
colleagues3 advocate for a combination of induced 
sputum and six-lobe lavage as the new standard of care 
for lower airway pathogen surveillance. They also make 
a case for the use of induced sputum as a non-invasive 
surrogate for bronchoalveolar lavage in symptomatic 
patients and propose that bronchoalveolar lavage 
should be reserved for patients with persistent signs 
or symptoms not explained by sputum induction. In 
symptomatic patients, induced sputum will correctly 
describe pathogens in almost two-thirds of cases 
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and, if correctly used, might reduce the need for 
bronchoscopy. 
Importantly, five (13%) of the total 39 pathogens 
identified were only detected by the induced sputum 
technique. This highlights an issue often encountered 
in diagnostic studies, of how to best define the gold 
standard. For example, bacteria found only from 
cough swabs, but not lower airway samples, will 
easily be discounted as normal commensal throat 
flora. The same suggestion could be made for induced 
sputum, as these samples pass the upper airways 
during collection. However, the authors suggest 
that the pathogens that were identified solely from 
induced sputum might be from the large intrathoracic 
airways, which are bypassed in a bronchoalveolar 
lavage procedure. This seems reasonable, particularly 
as bacterial bronchitis is common in symptomatic 
children with cystic fibrosis. Rather than discarding 
the pathogens that were exclusively found on 
induced sputum, the authors have included them in 
a combined gold standard, thereby highlighting the 
additional value that sputum induction might have 
for pathogen detection in symptomatic children with 
cystic fibrosis.
Care should be taken to not simply extrapolate results 
from the smaller subgroup of Ronchetti and colleagues’ 
study.3 Only small numbers of children younger than 
6 years were recruited, and the sample was too small 
to enable a separate analysis of children younger than 
6 years. Also, for most samples taken in the part of the 
study comparing sputum induction with bronchoalveolar 
lavage, participants were symptomatic (ie, had respiratory 
exacerbations).
The distinction between asymptomatic young 
children and symptomatic older children is important. 
Cystic fibrosis lung disease starts in the small airways 
and in young children, infection might be present in 
the absence of symptoms.7 Induced sputum might 
miss infection that will lead to structural lung damage 
in young asymptomatic children. Indeed, the largest 
study thus far that compared 61 paired sputum 
induction and bronchoalveolar lavage samples from 
young asymptomatic children suggested that induced 
sputum samples only had a 36·8% (95% CI 16·3–61·6) 
sensitivity to detect microbiota from the lower airway in 
cystic fibrosis using bronchoalveolar lavage as the gold-
standard method.8
Infancy and the early preschool years comprise a 
vital period when structural changes in the lungs of 
people with cystic fibrosis begins.7 Therefore, while 
Ronchetti and colleagues3 provide robust evidence for 
the usefulness of sputum induction in symptomatic 
older children with cystic fibrosis, future efforts should 
be focused on developing an accurate non-invasive 
method for microbiological surveillance in young 
asymptomatic children.
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